Dana Investment Advisors Inc. Reduces Stake in Elevance Health, Inc. $ELV

Dana Investment Advisors Inc. cut its position in shares of Elevance Health, Inc. (NYSE:ELV) by 49.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,338 shares of the company’s stock after selling 14,047 shares during the period. Dana Investment Advisors Inc.’s holdings in Elevance Health were worth $4,633,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. raised its stake in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares during the last quarter. Activest Wealth Management increased its holdings in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares in the last quarter. Rossby Financial LCC raised its position in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the last quarter. Vermillion & White Wealth Management Group LLC raised its position in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after acquiring an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. purchased a new stake in shares of Elevance Health in the second quarter valued at about $32,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ELV shares. Truist Financial cut their price objective on Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. upped their price objective on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Leerink Partners increased their price objective on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday, January 29th. Finally, Sanford C. Bernstein cut their target price on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $326.91 on Wednesday. The company has a market cap of $72.15 billion, a P/E ratio of 13.01, a P/E/G ratio of 1.86 and a beta of 0.50. The business has a fifty day simple moving average of $351.36 and a 200-day simple moving average of $335.31. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a $1.72 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.